- Home
- PROK
PROK
ProKidney Corp.
as 11-15-2024 4:00pm EST
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WINSTON-SALEM |
| Market Cap: | 220.6M | IPO Year: | N/A |
| Target Price: | $4.50 | AVG Volume (30 days): | 437.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $4.44 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ProKidney Corp. (PROK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weber Darin J. | PROK | Chief Regulatory Officer | Sep 19 '24 | Sell | $2.50 | 16,412 | $41,030.00 | 103,480 |
Latest ProKidney Corp. News
PROK Breaking Stock News: Dive into PROK Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
ProKidney Q3 Net Loss Narrows; Cash on Hand to Fund Operations Until 2027
GlobeNewswire
5 days ago
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
GlobeNewswire
12 days ago
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
GuruFocus.com
a month ago
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
Simply Wall St.
a month ago
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
GlobeNewswire
a month ago
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
GlobeNewswire
a month ago
ProKidney to Participate in the UBS Virtual Organ Restoration Day
MT Newswires
2 months ago
JPMorgan Initiates Coverage on ProKidney With Neutral Rating
Compare PROK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PROK ProKidney Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.